Emory University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Emory University sits in the top decile of US sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count).
Emory University: 1,208 sponsored US clinical trials, 208 recruiting.
Emory University sponsors 1,208 registered US clinical trials on ClinicalTrials.gov, 208 of them currently recruiting, and 767 completed. 170 of these trials are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 12 trials.
Top-decile sponsor footprint
Emory University ranks in the top decile of sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
767 of 926 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,208 total, page 4 of 25
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
NCT05493566
Ventricular Tachycardia Mechanisms
NCT05478213
Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer
NCT05368428
Upper Extremity Life Care Specialist (LCS)
NCT05422014
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT05464810
Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
NCT05244239
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
NCT05208307
Mental Stress Reactivity in Women With CMD
NCT05401630
DECIDE: Dyads and Families
NCT05139290
Effects of Lung Volume on Upper Airway Patency During Drug Induced Sleep Endoscopy
NCT05350332
Early Diagnostic Response Model (EDRM)
NCT05419895
Influenza Human Challenge Model
NCT05332899
Tumor Treating Fields for the Treatment of Brainstem Gliomas
NCT05310448
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
NCT05039073
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
NCT05103904
Telemedicine in Early Childhood Constraint Therapy in Cerebral Palsy
NCT04997109
Botulinum Toxin in Raynaud's Phenomenon
NCT05125029
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
NCT04776395
Mechanistic Interventions and Neuroscience of Dissociation
NCT04670640
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
NCT04883437
Cortical Electrophysiology of Response Inhibition in Parkinson's Disease
NCT06234995
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
NCT04878029
Personalized Autologous Transplant for Multiple Myeloma
NCT04483206
Childhood Cancer Predisposition Study (CCPS)
NCT04511806
Comprehensive Esophageal Diagnostics Study
NCT04641702
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
NCT04762199
Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer
NCT04725903
Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
NCT04590664
Opioid-Free Orthopaedics
NCT04659317
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
NCT04469530
Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer
NCT04428671
Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer
NCT04342429
Treatment of Hemophilia A Patients With FVIII Inhibitors
NCT04023019
Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study
NCT04278118
Brain Stimulation and Decision-making
NCT04099056
Partnered Rhythmic Rehabilitation in Prodromal Alzheimer's Disease
NCT04029623
Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)
NCT04404530
Mindfulness in Chronic Kidney Disease
NCT04099992
Exercise in Patients Undergoing Urologic Surgery
NCT03954678
Role of Body Fat Distribution in Metabolic and Pulmonary Decline in Cystic Fibrosis (ORBIT-CF)
NCT04002882
2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers
NCT03800693
Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients With Brain Tumors
NCT04908709
VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
NCT03690986
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
NCT03501576
Assessing the Tendons With Shear Wave Elastography
NCT03456778
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
NCT03304821
Communication Issues in Patient and Provider Discussions of Immunotherapy
NCT05873608
Neurovascular Transduction During Exercise in Chronic Kidney Disease
NCT02947750
Improving Health Literacy in African-American Prostate Cancer Patients
NCT03322891
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
NCT02604277
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 154 |
| Phase 2 | 190 |
| Phase 3 | 36 |
| Phase 4 | 134 |
Therapeutic Areas
What is open in the Emory University pipeline
208 recruiting of 1,208 indexed (17% open); 767 completed (63%).
Phase mix: 170 late (III/IV) vs 344 early (I/II) (early-phase heavy).
Top condition: Depression (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Emory University: open-pipeline peers nationwide
Peers matched on 1,208 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,208 trials (± recruiting share)
- Northwestern University · 1,209 trials · 15% recruiting
- University of Pittsburgh · 1,238 trials · 13% recruiting
- NYU Langone Health · 1,164 trials · 17% recruiting
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Baylor Research Institute · 17% recruiting · 180 trials
- National Institute on Alcohol Abuse and Alcoholism (NIAAA) · 17% recruiting · 93 trials
- Hunter College of City University of New York · 17% recruiting · 29 trials
- Ochsner Health System · 17% recruiting · 29 trials
Related
What to do with this Emory University page
1,208 registered trials is a research-attention snapshot, not an endorsement of Emory University or any single study.
- 208 of Emory University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition Emory University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Emory University pipeline card: 1,208 registered trials from official public datasets.Report a data error.